A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432791/
https://www.ncbi.nlm.nih.gov/pubmed/22002018
http://dx.doi.org/10.1007/s10637-011-9753-y
_version_ 1782242248324284416
author Wang-Gillam, Andrea
Tew, William P.
Rothenberg, Mace L.
Dupont, Jakob
Cooper, Wendy
Sternas, Lars
Buzenet, Giliane
Sosman, Jeffrey A.
Spriggs, David R.
Lockhart, Albert Craig
author_facet Wang-Gillam, Andrea
Tew, William P.
Rothenberg, Mace L.
Dupont, Jakob
Cooper, Wendy
Sternas, Lars
Buzenet, Giliane
Sosman, Jeffrey A.
Spriggs, David R.
Lockhart, Albert Craig
author_sort Wang-Gillam, Andrea
collection PubMed
description Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.
format Online
Article
Text
id pubmed-3432791
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-34327912012-09-07 A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors Wang-Gillam, Andrea Tew, William P. Rothenberg, Mace L. Dupont, Jakob Cooper, Wendy Sternas, Lars Buzenet, Giliane Sosman, Jeffrey A. Spriggs, David R. Lockhart, Albert Craig Invest New Drugs Phase I Studies Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks. Springer US 2011-10-15 2012 /pmc/articles/PMC3432791/ /pubmed/22002018 http://dx.doi.org/10.1007/s10637-011-9753-y Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Phase I Studies
Wang-Gillam, Andrea
Tew, William P.
Rothenberg, Mace L.
Dupont, Jakob
Cooper, Wendy
Sternas, Lars
Buzenet, Giliane
Sosman, Jeffrey A.
Spriggs, David R.
Lockhart, Albert Craig
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title_full A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title_fullStr A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title_full_unstemmed A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title_short A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
title_sort phase i study of subcutaneously administered aflibercept (vegf trap) in a new formulation in patients with advanced solid tumors
topic Phase I Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432791/
https://www.ncbi.nlm.nih.gov/pubmed/22002018
http://dx.doi.org/10.1007/s10637-011-9753-y
work_keys_str_mv AT wanggillamandrea aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT tewwilliamp aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT rothenbergmacel aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT dupontjakob aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT cooperwendy aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT sternaslars aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT buzenetgiliane aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT sosmanjeffreya aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT spriggsdavidr aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT lockhartalbertcraig aphaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT wanggillamandrea phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT tewwilliamp phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT rothenbergmacel phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT dupontjakob phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT cooperwendy phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT sternaslars phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT buzenetgiliane phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT sosmanjeffreya phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT spriggsdavidr phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors
AT lockhartalbertcraig phaseistudyofsubcutaneouslyadministeredafliberceptvegftrapinanewformulationinpatientswithadvancedsolidtumors

Ejemplares similares